Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

Blood advances - 23 Feb 2021

Hunter Anthony M, Komrokji Rami S, Yun Seongseok, Al Ali Najla, Chan Onyee, Song Jinming, Hussaini Mohammad, Talati Chetasi, Sweet Kendra L, Lancet Jeffrey E, Padron Eric, List Alan F, Sallman David A

Abstract excerpt

Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes (MDSs), yet identifying those patients unlikely to benefit remains challenging. We assessed response and overall survival (OS) in 247 patients molecularly profiled by next-generation sequencing (NGS) before first-line HMA therapy, and a subset of 108 patients were sequenced serially during treatment. The most common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33591325
DOI: 10.1182/bloodadvances.2020003508
PMCID: PMC7903224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.PMID 33591325Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.Semantic proximity Read ↗

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Mutations and karyotype predict treatment response in myelodysplastic syndromes.Semantic proximity Read ↗

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.Semantic proximity Read ↗

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.Semantic proximity Read ↗

The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.Semantic proximity Read ↗

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.